Please ensure Javascript is enabled for purposes of website accessibility

Is Sorrento Therapeutics Stock a Buy After Its Promising Coronavirus News?

By Keith Speights – May 19, 2020 at 7:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's experimental antibody holds the potential to neutralize the novel coronavirus that causes COVID-19. Time to buy Sorrento?

You know a company has some really good news when its stock skyrockets 144% in a single day. That's exactly what Sorrento Therapeutics (SRNE 6.77%) shares did on Friday. And it looked like the biotech's momentum would keep going on Monday, with Sorrento soaring more than 40% early before giving up its additional gains.

Sorrento indeed had some really good news. The company announced Friday morning that its experimental antibody STI-1499 was able to completely inhibit infection by the novel coronavirus in a preclinical test. With this promising news, is Sorrento Therapeutics stock a buy? 

Gloved hand holding a petri dish with other petri dishes on a table

Image source: Getty Images.

Just how good is Sorrento's news?

To be sure, Sorrento's preclinical data is encouraging. The company said that it screened billions of different antibodies to identify the most promising candidates for defending against infection by the novel coronavirus. STI-1499 stood out as the best of the bunch at neutralizing the virus that causes COVID-19. 

Also, Sorrento's previously announced approach of developing an antibody cocktail seems like a smart strategy. The company expects that STI-1499 will be the first antibody in its experimental cocktail. 

Investors and the public in general rightfully cheered Sorrento's update. Before we let the cart get ahead of the horse, though, it's important to note that tests conducted in test tubes and petri dishes in a lab don't always translate to success in human clinical testing. And Sorrento's announcement late last week pertained only to results from a lab test.

Sorrento must first advance its STI-1499 into an early stage clinical study. Success is far from a slam dunk even after that point. Fewer than one out of five experimental drugs targeting infectious diseases that make it to a phase 1 clinical trial go on to win FDA approval, according to historical data compiled by biopharmaceutical industry trade organization BIO.

The rest of the story

Sorrento currently has one approved product, ZTlido, which was launched commercially in October 2018 as a treatment for pain associated with shingles. ZTlido is a topical delivery for lidocaine, a local anesthetic that's been around for more than 70 years. Outside of ZTlido, Sorrento hasn't completed any clinical trials thus far. 

ZTlido hasn't been a huge moneymaker. Sorrento's product revenue totaled only $5.2 million in the first quarter. Even with service revenue of nearly $2.5 million added to its revenue total, the company is spending a lot more than it's making. Sorrento posted a net loss of $69.2 million in Q1. Even worse, it doesn't have a lot of cash remaining to fund operations. The drugmaker ended the first quarter with cash and cash equivalents totaling $21.9 million. 

Without raising additional capital, the company won't be able to keep the lights on much less fund clinical studies for its coronavirus program. In March, Sorrento filed a shelf registration statement with the Securities and Exchange Commission that paves the way for offering up to $1 billion in securities, including issuing new shares. It's a virtual certainty that a stock offering is on the way in the near future. That means the value of existing shares will be diluted.

In the meantime, Sorrento said that it's trying to obtain government support as well as potentially line up pharmaceutical partners to scale up its manufacturing capacity for STI-1499. This financial assistance would be a must for the company to deliver on its ambitious goal of producing millions of doses of the antibody.

Answering the question

So is Sorrento Therapeutics stock a buy right now? If the company is successful with its experimental COVID-19 drug, the stock will launch into orbit. But despite the promising preclinical results, there's still a long way to go and a lot of hurdles to be jumped. 

If STI-1499 doesn't pan out in clinical trials, all of Sorrento's recent gains will evaporate. Investors should ask themselves if they're willing to take the risk of losing half of their money or even more in exchange for the possibility of making several times their initial investment. My answer to this question is a resounding "no." I think that there are too many uncertainties for Sorrento to be a compelling stock to buy at this point.

I'd prefer to see how STI-1499 fares in at least two phases of clinical studies. These studies will shed light on how safe and effective the antibody truly is. For now, I think that there are other biotech stocks, including some with promising COVID-19 programs, that offer more attractive risk-reward propositions.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$1.66 (6.77%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.